Alzheimer's disease is characterized by the accumulation and spread of amyloid-β (Aβ) plaques and tau neurofibrillary tangles, which are believed to drive neuronal dysfunction, cell death, and cognitive decline.1 However, to date, therapies designed to target these hallmark pathologies have yielded, at best, modest clinical benefits,2 underscoring the critical need for novel treatment strategies. Here, MAPT is linked to Mental deterioration.